Cargando…
Lipid Lowering Therapy and Circulating PCSK9 Concentration
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events. As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels...
Autor principal: | Nozue, Tsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587514/ https://www.ncbi.nlm.nih.gov/pubmed/28804094 http://dx.doi.org/10.5551/jat.RV17012 |
Ejemplares similares
-
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019) -
PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017) -
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017) -
LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021) -
PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)